利妥昔单抗在复发或难治性系统性红斑狼疮缓解诱导后作为维持治疗的研究
这项多中心前瞻性观察性非随机队列研究纳入82例对利妥昔单抗诱导治疗有临床反应的复发或难治性系统性红斑狼疮患者,比较利妥昔单抗维持治疗与传统免疫抑制剂维持治疗的疗效与安全性。中位随访24个月,利妥昔单抗组无复发生存率高于传统免疫抑制剂组,多因素分析确定羟氯喹使用、利妥昔单抗维持治疗和血液系统受累为持续缓解的独立预测因素。
要点
- 82例患者中67例(81.7%)在6个月时对利妥昔单抗诱导治疗有临床反应。
- 中位随访24个月,利妥昔单抗组3例复发,传统免疫抑制剂组10例复发。
- 利妥昔单抗维持治疗组无复发生存率高于传统免疫抑制剂组。
核心结论
- 长期利妥昔单抗维持治疗对利妥昔单抗诱导治疗有临床反应的复发或难治性系统性红斑狼疮患者具有高疗效和可接受的安全性。
研究设计与样本
- 多中心前瞻性观察性非随机队列研究,纳入四个中心的82例至少接受过一个疗程利妥昔单抗诱导治疗的系统性红斑狼疮患者。
- 将对利妥昔单抗有临床反应的患者根据前12个月维持治疗方案分为利妥昔单抗组和传统免疫抑制剂组。
主要发现
- 82例患者中67例(81.7%)在6个月时有临床反应;34例(50.7%)接受利妥昔单抗维持治疗,33例(49.3%)接受传统免疫抑制剂维持治疗。
- 中位随访24个月,共13例(19.4%)患者复发,其中利妥昔单抗组3例,传统免疫抑制剂组10例。
- 利妥昔单抗组无复发生存率高于传统免疫抑制剂组。
- 多因素分析确定羟氯喹使用、利妥昔单抗维持治疗和血液系统受累为持续缓解的独立预测因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the efficacy and safety of rituximab (RTX) maintenance therapy compared with traditional immunosuppressive agent (ISA) maintenance therapy in patients with relapsing or refractory SLE. METHODS: It is a prospective observational non-randomized cohort study. The study enrolled SLE patients in four centres who had received at least one course of RTX induction treatment. Patients with a clinical response to RTX were divided into two groups based on their maintenance therapy in the first 12 months: the RTX group and the ISA group. The relapse-free survival times were compared between the two groups. Univariate and multivariate analyses were conducted to identify predictive factors for disease relapse. RESULTS: Among the 82 patients included in the cohort, 67 (81.7%) patients had a clinical response at 6 months. RTX maintenance therapy was applied in 34 (50.7%) patients and ISA maintenance therapy was applied in the remaining 33 (49.3%) patients. After a median follow-up of 24 months, a total of 13 (19.4%) patients had experienced disease relapse, comprising three in the RTX group and 10 in the ISA group. Patients in the RTX group had a higher relapse-free survival rate than patients in the ISA group. Multivariate analysis identified hydroxychloroquine use, RTX maintenance therapy and haematological system involvement as independent predictors for sustained remission. CONCLUSION: This multicentre prospective cohort study demonstrated that long-term RTX maintenance therapy has high efficacy and acceptable safety in relapsing or refractory SLE patients who had a clinical response to RTX induction therapy.
引用
- Chen X, Shi X, Xue H, et al. Rituximab as maintenance therapy following remission induction in relapsing or refractory systemic lupus erythematosus. Rheumatology (Oxford). 2023. PMID: 35976105. doi:10.1093/rheumatology/keac471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。